Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Revenue	-0.3	1.43	0	10.05	9.68	7.31
Revenue Growth (YoY)	-	-	-	3.85%	32.35%	23.48%
Cost of Revenue	-1.58	0	0	4.93	4.56	4.27
Gross Profit	1.27	1.43	0	5.12	5.12	3.05
Selling, General & Admin	19.11	21.06	5.57	7.13	7.55	6.85
Research & Development	24.91	21.31	0.85	1.43	1.13	1.47
Other Operating Expenses	-0.02	0	0	0.01	-0.07	-0.02
Operating Expenses	43.99	42.38	6.42	8.57	8.6	8.3
Operating Income	-42.72	-40.94	-6.42	-3.45	-3.48	-5.25
Interest Expense / Income	0.1	0.08	0	0	0	0
Other Expense / Income	7.76	8.13	0.85	-0.06	-0.03	-0.11
Pretax Income	-50.57	-49.16	-7.27	-3.39	-3.45	-5.14
Income Tax	7.85	-2.65	0	0	0	0
Net Income	-58.42	-46.51	-7.27	-3.39	-3.45	-5.14
Preferred Dividends	0	0	0	0	0.01	0.01
Net Income Common	-58.42	-46.51	-7.27	-3.39	-3.46	-5.16
Shares Outstanding (Basic)	50	27	14	10	7	7
Shares Outstanding (Diluted)	50	27	14	10	7	7
Shares Change	116.59%	88.50%	36.74%	53.61%	0.83%	21.54%
EPS (Basic)	-1.90	-1.70	-0.50	-0.30	-0.50	-0.80
EPS (Diluted)	-1.90	-1.70	-0.50	-0.30	-0.50	-0.80
Free Cash Flow	-23.29	-37.99	-7.98	-3.22	-3.91	-5.46
Free Cash Flow Per Share	-0.47	-1.42	-0.56	-0.31	-0.58	-0.81
Gross Margin	-	100.00%	-	50.94%	52.93%	41.66%
Operating Margin	-	-2855.02%	-	-34.28%	-35.91%	-71.83%
Profit Margin	-	-3243.24%	-	-33.72%	-35.71%	-70.48%
Free Cash Flow Margin	-	-2648.88%	-	-32.00%	-40.43%	-74.64%
EBITDA	-49.22	-48.01	-6.98	-3.2	-3.26	-4.96
EBITDA Margin	-	-3348.26%	-	-31.80%	-33.65%	-67.79%
Depreciation & Amortization	1.25	1.06	0.29	0.19	0.19	0.19
EBIT	-50.48	-49.08	-7.27	-3.39	-3.45	-5.14
EBIT Margin	-	-3422.25%	-	-33.69%	-35.60%	-70.33%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).